Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board of directors and management of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) on behalf of its investors [1][2]. Group 1: Investigation Details - The investigation aims to determine if the Verrica board has breached its fiduciary duties to shareholders [2]. - Shareholders are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [2]. Group 2: Firm Background - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Amylyx Pharmaceuticals, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Summary by Relevant Sections Allegations of Misconduct - The complaint asserts that the Individual Defendants made false and misleading statements regarding the Relyvrio commercial launch, claiming significant demand that was not sustainable [2]. - It is alleged that the initial surge in demand for Relyvrio was temporary and had already subsided within months of its launch, undermining growth potential among newly diagnosed ALS patients [2]. - The complaint highlights that there were high, undisclosed discontinuation rates for Relyvrio, which negatively impacted the drug's commercial viability and inflated the perceived potential for acquiring new patients [2]. Legal Representation - Bragar Eagel & Squire, P.C. is representing long-term stockholders of Amylyx and is open to inquiries regarding the claims and rights of investors [3]. Firm Background - Bragar Eagel & Squire, P.C. is a recognized law firm specializing in representing individual and institutional investors in various complex litigations across state and federal courts [4].